Aakash Desai: FDA approves a biparatopic, Zanidatamab – targeting HER2 for BTCs
Aakash Desai, Associate Director and Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“FDA Oncology approves a biparatopic, Zanidatamab – targeting HER2 for biliary tract cancers based on HERIZON-BTC-01!
– ORR: 41.3%, mDOR=14.9 mths
– Approval for IHC 3+, where TDX-d also has agnostic approval
– 18% Gr3 TRAEs, diarrhea.”
Authors: James J Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Phillippe Metges, Jie’er Ying, John Bridgewater, Myung-Ah Lee, Mohamedtaki A Tejani, Emerson Y Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip Garfin, Shubham Pant
More posts featuring Aakash Desai.
Further Reading:
U.S. FDA Approval of Ziihera for the Previously Treated, Unresectable or IHC 3+ Biliary Tract Cancer
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023